TSTakayuki Saitoh

Takayuki Saitoh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takayuki Saitoh has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and Safety of Intermediate dose Etoposide for Mobilization of Peripheral Blood Stem Cells in Hematopoietic Tumors

    by Takuma Ishizaki, Akihiko Yokohama, Hiroaki Shimizu, Kunio Yanagisawa, Yoshiyuki Ogawa, Takeki Mitsui, Hiromi Koiso, Makiko Takizawa, Takayuki Saitoh, Hirokazu Murakami, et al.

    再発難治悪性リンパ腫や若年者症候性多発性骨髄腫に対し,自家末梢血幹細胞移植が標準治療として行われている.移植後の速やかな生着には2.0×106/kgのCD34陽性細胞が必要とされ,末梢血幹細胞採取効率の向上が期待される.当科で2000年12月から2015年3月までに末梢血幹細胞採取(Peripheral blood stem cell harvest: PBSCH)を行った悪性リンパ腫と多発性骨髄腫の82例のうち,動員化学療法としてetoposide中等量療法(350 mg/m2,4日間)を施行した19例を対象として,その有効性と安全性を検討した.15例(79%)で必要量のCD34陽性細胞の採取を達成した.白血球数1000/μl以下の期間中央値は5日間(3日~7日)で,37.5度以上の発熱は解析可能な13例中9例に認め,菌血症の1例以外は発熱性好中球減少症で,全例抗菌薬治療が奏効した.Grade 3の口腔粘膜炎を1例に認めたが,それ以外に重篤な有害事象はなかった.Etoposide中等量療法は有効で安全な動員化学療法と考えられた.

    • 1 March 2015
      • Vol. 63  (3) , 305-11

    High Frequency of Hepatitis B Core and Surface Antibodies in Hepatitis C Virus-Infected Patients on the Screening Examination.

    by Chiaki Suto, Hirokazu Murakami, Yoshino Kobayashi, Takeaki Nagamine, Takayuki Saitoh, Tetsuhiro Kasamatsu, Hatsue Ogawara, Masami Murakami

    Hepatitis B virus (HBV) and hepatitis C virus (HCV) are important human pathogens that cause chronic liver disease and hepatocellular carcinoma. Co-infection of HBV and HCV is not uncommon, particularly in countries where these two viruses are endemic. Therefore, the characteristics of HBV co-infection in HCV antibody (HCVAb) -positive Japanese patients found on the screening examination were analyzed. Between January and December 2011, HCVAb status was evaluated as the screening examination in 12,582 patients in Gunma University Hospital, and it was positive in 402 patients (3.2%). In 331 HCVAb-positive/HBs antigen (HBsAg) -negative patients with available residual serum, HBs antibody (HBsAb) and HBc antibody (HBcAb) were examined. In addition, HCV-RNA was examined in 291 patients with available residual serum. HBV-DNA and HBV core-related antigen (HBcrAg) were examined in 106 patients with available residual serum. The HCVAb titer was distributed between 1 and 18 sample/cutoff index (S/CO). 275 patients (83.1%) had a high HCVAb titer (S/CO ≥10). HCV-RNA was positive in 230 (79.0%) patients, and it was more frequently detected in HCVAb high-titer patients (88%) than in low-titer patients (32%; p < 0.0001); 61 (18.4%) and 101(30.5%) patients were positive for HBsAb and HBcAb, respectively. Of 230 HCV-RNA-positive patients, 38 (16.5%) and 59 (25.6%) were positive for HBsAb and HBcAb, respectively. Three (2.8%) and 2 (1.9%) of 106 patients had HBV-DNA and HBVCrAg. The ALT level was higher than 30 IU/L in 146/327 (44.6%) HCVAb-positive patients who had ALT levels measured. Abnormal ALT elevation was more frequent in HCVAb high-titer patients than in low-titer patients (48.3% vs. 26.8%; p = 0.0031), and in HCV-RNA-positive patients than in HCV-RNA-negative patients (54.2% vs. 13.3%; p < 0.001). HBV reactivation should be noted in these HCVAb-positive/HBsAg-negative patients on the screening examination if these patients must receive chemotherapy or immunosuppressive therapy. In addition, surveying of HBsAb in addition to HBcAb is also necessary.

    • 1 January 2015
      • Vol. 73  (1) , 156-61

    [Immunomodulatory effects of lenalidomide].

    by Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami

    Immunomodulatory drugs (IMiDs) including lenalidomide, a single compound shows various pharmacological action such as the stimulation of T cells and natural killer (NK) cells, the suppression hematopoietic tumor proliferation, suppression of neo-vascularisation, and anti-inflammatory action. It has been thought that IMiDs stimulates CD8+ cytotoxic T cells primarily, it is recently shown that they also stimulate CD4+ helper-T cells similarly. Lenalidomide stimulates T cells and NK-cell through production of Th1 type cytokines IL-2 and IFN-γ from CD4+ helper-T cells. Lenalidomide also activate T cells indirectly by inhibiting regulatory T cells and myeloid derived suppressor cells (MDSC) which inhibit the activation of T cells, but controversy still exist about effects on regulatory T cells.


  • A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents

    by Hirono Iriuchishima, Takayuki Saitoh, Hiroshi Handa, Atsushi Isoda, Morio Matsumoto, Morio Sawamura, Atsushi Iwasaki, Chiaki Ushie, Hikaru Hattori, Yoshiko Sasaki, et al.

    Various prognostic markers for multiple myeloma (MM) have been identified, and stratification using these markers is considered important to optimize treatment strategies. The international staging system (ISS) is now a widely accepted prognostic staging system for MM patients; however, its validity is controversial in the era of new therapeutic regimens, since ISS had been established before introduction of new agents. We retrospectively reviewed prognostic factors in order to seek out an alternative staging system more suitably applied to MM patients treated with novel agents. We analyzed 178 newly diagnosed MM patients who received either conventional chemotherapy without novel agents (CT; n = 79) or chemotherapy with novel agents (NT; n = 99). Although median overall survival (OS) of patients treated with CT is significantly different depending on stages of ISS, ISS had no effect on OS among patients treated with NT. Meanwhile, we identified hemoglobin (Hb) and plasmacytoma as independent risk factors for OS in patients who received NT. Using these two parameters, we stratified NT patients into three stages; stage 1 (Hb≥10 g/dL and absence of plasmacytoma), stage 2 (not stage 1 or 3), and stage 3 (Hb <10 g/dL and presence of plasmacytoma). We found that there were significant differences in median OS among the three stages (8.13, 5.95, and 2.45 yr for stages 1, 2, and 3, respectively). This preliminary study suggests that this alternative staging system based on Hb and plasmacytoma is a simple and useful way to predict prognosis of MM patients in the novel agent era.


    • 1 June 2014
      • Vol. 55  (6) , 687-91

    [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].

    by Makiko Takizawa, Akihiko Yokohama, Tomomi Sekigami, Hiromi Koiso, Takuma Ishizaki, Takeki Mitsui, Yoshiyuki Ogawa, Takayuki Saitoh, Hiroshi Handa, Norifumi Tsukamoto, et al.

    Herein, we report a patient with polycythemia vera (PV) who exhibited Philadelphia chromosome (Ph) positive CML-like clinical features after 13 years of hydroxycarbamide administration and successful treatment with a tyrosine kinase inhibitor (TKI). She was 64 years old when initially diagnosed with PV and was confirmed to be negative for BCR-ABL translocation. Thirteen years later, with increasing white blood cell and platelet counts, a BCR-ABL positive clone emerged and the JAK2V617F mutation disappeared. After TKI treatment, the BCR-ABL copy number decreased and the JAK2V617F mutation was again detected. Furthermore, MPN clinical features were observed. This case provides insights into the clonal divergence and growth advantage of the Ph positive clone over the MPN clone. Whether JAK2V617F is an MPN initiating event or a secondary mutation has been a point of discussion for the past several years. This issue is also considered in the present report.

    • 1 February 2014
      • Vol. 55  (2) , 244-8

    [Relapsed primary intraocular lymphoma treated with intravitreal methotrexate and high-dose chemotherapy followed by autologous stem cell rescue].

    by Tadashi Kamio, Akihiko Yokohama, Toshimasa Hayashi, Kotaro Toyama, Hiroko Koya, Takumi Hoshino, Takayuki Saitoh, Naoto Hanyuda, Ryou Mukai, Hiroshi Handa, et al.

    A 58-year-old woman with primary intraocular lymphoma (PIOL) of her right eye was treated with combination chemotherapy (methotrexate, procarbazine and vincristine) followed by irradiation to her brain and right eye. However, the disease recurred in the right eye four months later. She was treated with intravitreal injection of methotrexate and high-dose chemotherapy in combination with autologous stem cell transplantation after salvage therapy consisting of cytarabine, etoposide and rituximab. With this treatment strategy, she has been in remission for more than one year with no deterioration of either leukoencephalopathy or cognitive function. Intravitreal injection of methotrexate and high-dose chemotherapy may now be regarded as one of the treatment choices for relapsed PIOL.


  • DNMT3B7 expression related to MENT expression and its promoter methylation in human lymphomas

    by Lobna Alkebsi, Hiroshi Handa, Yoshiko Sasaki, Yohei Osaki, Kunio Yanagisawa, Yoshiaki Ogawa, Akihiko Yokohama, Hikaru Hattori, Hiromi Koiso, Takayuki Saitoh, et al.


  • Distinctive disease subgroups according to differentiation stages in adult patients with T‐cell acute lymphoblastic leukemia

    by Hiroaki Shimizu, Hiroshi Handa, Nahoko Hatsumi, Satoru Takada, Takayuki Saitoh, Toru Sakura, Shuichi Miyawaki, Yoshihisa Nojima

    Objectives The categorization of T‐cell acute lymphoblastic leukemia (T‐ALL) into four subgroups according to the degree of thymic differentiation was proposed in 1995, and this categorization scheme has been described in the World Health Organization classification 4th edition with minor changes. The aim of this study is to explore the clinical significance of leukemia cell differentiation stages in patients with T‐ALL. Methods We analyzed 36 adult T‐ALL patients, including six patients (17%) in pro‐T stage, 16 (44%) in pre‐T stage, three (8%) in cortical‐T stage, and 11 (31%) in medullary‐T stage. Pro‐T and pre‐T stages were arbitrarily clustered as the immature group, and cortical‐T and medullary‐T stages as the mature group. Results Patients in the immature group had unique presentations, including lower lactate dehydrogenase levels, lower frequency of mediastinal tumor, and higher expression of myeloid antigens than the mature group. There was no difference in the treatment strategies between both groups. Although patients in the immature group had a lower complete remission (CR) rate when compared with the mature group (45% vs. 79%, respectively; P = 0.04), the 3‐yr overall survival (OS) for both groups was comparable (27% vs. 38%, respectively; P = 0.66). Such discrepancy between the CR rates and the OS could be partially explained by survival benefit of allogeneic transplantation observed in the immature group but not in the mature group. Conclusions These findings indicate that T‐ALL patients can be categorized into two biologically distinctive subgroups according to the differentiation stages, and this stratification might enable prospective identification of patients with poor chemotherapy response.


    • 1 February 2013
      • Vol. 54  (2) , 214-8

    [Emergence of donor-derived anti-HLA antibody and subsequent transfusion-refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor in a patient with acute myeloid leukemia].

    by Yuri Uchiyama, Takumi Hoshino, Masahiro Mihara, Takeki Mitsui, Hiromi Koiso, Makiko Takizawa, Akihiko Yokohama, Takayuki Saitoh, Hideki Uchiumi, Hiroshi Handa, et al.

    A 45-year-old woman with acute myelogenous leukemia developed platelet transfusion refractoriness (PTR) after the engraftment of an allogeneic peripheral blood stem cell transplantation (PBSCT) from her multiparous sister, which was attributed to HLA antibodies that could not be detected in the patient's serum before transplantation. She achieved neutrophil engraftment by day 18 and megakaryocytopoiesis and complete donor chimerism was confirmed in the bone marrow on day 21. IgG-class HLA antibodies were detected in her serum on day 24 after PBSCT; however, on day 15, no HLA antibodies were detected. The specificity of the antibodies that emerged in the patient closely resembled that of the antibodies found in the donor. The donor had probably been immunized during pregnancy by their partner's HLA-antigens expressed by the fetus. Consequently, transplanted donor-derived cells provoked HLA antibodies in the recipient early after PBSCT, and those HLA antibodies induced PTR. The presence of HLA antibodies should be examined at least in pregnant female donors whose recipients developed PTR attributable to HLA antibodies after SCT.


    • 1 April 2012
      • p. 584-8

    [Diagnosis and prognostic factors in patients with multiple myeloma].

    by Hirokazu Murakami, Akihiko Yokohama, Takayuki Saitoh, Norifumi Tsukamoto, Hiroshi Handa